OvaScience℠ (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Rodman & Renshaw 16th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., on Wednesday, September 10, 2014 at 10:25 am ET at the New York Palace Hotel.
A live audio webcast of the presentation can be accessed by visiting the Investor section of the Company’s website at www.ovascience.com. A replay of the webcast will be archived on the OvaScience website for two weeks following the presentation.
About OvaScience
OvaScience (NASDAQ: OVAS) is a global life
sciences company focused on the discovery, development and
commercialization of new fertility treatments. The Company’s patented
technology is based on the discovery of egg precursor cells (EggPCs),
which are found in the ovaries. By applying proprietary technology to
identify and isolate EggPC℠ cells, OvaScience is developing potential
next generation in vitro fertilization (IVF) treatments.
OvaScience launched the AUGMENT℠ treatment, which aims to improve egg
quality and increase the success of IVF, in international markets and
has two additional treatments in development: the OvaPrime℠ treatment,
designed to boost a woman’s egg reserve using her own EggPC cells; and
the OvaTure℠ treatment, which seeks to create mature
fertilizable eggs from a woman’s own EggPC cells without the need for
hormone injections. OvaScience’s team of scientists, physicians and
advisers includes recognized leaders in the field of reproductive
medicine. For more information, please visit www.ovascience.com
and connect with us on Twitter
and Facebook.
Forward-Looking Statements
This press release includes
forward-looking statements about the Company’s plans for the AUGMENT
treatment and its two fertility treatments in development. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important factors,
including risks related to: our expectation that the AUGMENT treatment
and OvaPrime treatment meet the requirements of a class of products
exempt from premarket review and approval under applicable regulations
in those countries where we have launched or plan to introduce the
AUGMENT treatment and plan to introduce the OvaPrime treatment; the
science underlying our treatment and treatments in development
(including the AUGMENT, OvaPrime and OvaTure treatments), which is
unproven; our ability to obtain regulatory approval where necessary for
our potential treatments; our ability to develop our potential
treatments, including the OvaPrime and OvaTure treatments, on the
timelines we expect, if at all; our ability to commercialize the AUGMENT
treatment and our potential treatments, including the OvaPrime
treatment, on the timelines we expect, if at all; as well as those risks
more fully discussed in the “Risk Factors” section of our most recently
filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K.
The forward-looking statements contained in this press release reflect
our current views with respect to future events. We anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking statements
in the future, we specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as representing our
view as of any date subsequent to the date hereof.
###
Contacts:
Cara Petralia, 617-714-9638
Director,
Corporate Communications
cpetralia@ovascience.com